These press releases are intended for business journalists and analysts/investors
Cervarix is approved for cervical cancer prevention in female population aged 9-45 years in mainland China
The age limit of Cervarixis approved to extend to 45 years, thereby benefiting more Chinese women
GSK announced today that Flixotide Nebules (generic name: Fluticasone Propionate Nebuliser Suspension) was officially launched in mainland China and provides a new option for the treatment of childhood asthma.
Today, the Chinese Association of STD and AIDS Prevention and Control (CASAPC; “the Association”) and GSK China launched the “Online Digital Physician Education Project” for AIDS prevention and control.
GSK China partners with JD to drive “Internet + Healthcare” to improve patient experience and access to healthcare
Today, GSK China and JD.com, China’s largest retailer, signed an MOU of strategic collaboration. Under the MOU, the two partners will fully leverage each other’s complementary strengths in healthcare, pharmaceuticals and internet applications and work together to create innovative solutions that improve patient experience across the whole healthcare ecosystem and value chain, from seeking treatment to receiving care and to managing health.
Landmark IMPACT study published in NEJM shows significant benefits of Trelegy for high risk patients with COPD
GSK recently announced the publication in the New England Journal of Medicine (NEJM) of the landmark IMPACT study, providing the evidence that high risk patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation can benefit from Trelegy including inhaled corticosteroids (“ICS”).
GSK and Innoviva, Inc. (Innoviva) today announced that a new once-daily dual bronchodilators treatment for chronic obstructive pulmonary disease (COPD) has been approved by the China Food and Drug Administration (CFDA).
GSK today announced that Triumeq (generic name: dolutegravir, abacavir and lamivudine all-in-one tablet), the innovative antiretroviral (ARV) drug by its subsidiary joint venture ViiV Healthcare1, was officially launched in mainland China.